Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Purdue Pharmaceuticals L.P

    Client Virtual Booth

    PURDUE PHARMACEUTICALS L.P

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Purdue Pharmaceuticals L.P
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    One Stamford Forum, 201 Tresser Boulevard, Stamford, Connecticut 06901-3431
    Telephone
    Telephone
    +1 (203) 588-8000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.purduepharma.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    FDA Accepts Filing of NDA for Nalmefene for the Treatment of Opioid Overdose
    FDA Accepts Filing of NDA for Nalmefene for the Treatment of Opioid Overdose

    https://www.businesswire.com/news/home/20240408735407/en

    BUSINESSWIRE
    08 Apr 2024
    Share Share
    Plan of Reorganization of Purdue Pharma L.P. Facilitates Creation of New Company
    Plan of Reorganization of Purdue Pharma L.P. Facilitates Creation of New Company

    https://www.businesswire.com/news/home/20210903005441/en

    BUSINESSWIRE
    03 Sep 2021
    Share Share
    Plan of Reorganization of Purdue Pharma L.P. Facilitates Creation of New Company
    Plan of Reorganization of Purdue Pharma L.P. Facilitates Creation of New Company

    https://www.businesswire.com/news/home/20210903005441/en

    BUSINESSWIRE
    03 Sep 2021
    Share Share
    States oppose settlement being negotiated by Purdue and Justice Department
    States oppose settlement being negotiated by Purdue and Justice Department

    https://www.reuters.com/article/us-purdue-pharma-opioids-investigations/u-s-states-oppose-settlement-being-negotiated-by-oxycontin-maker-purdue-and-justice-department-letter-idUSKBN26Z2WJ

    Mike Spector REUTERS
    15 Oct 2020
    Share Share
    OxyContin maker Purdue nears guilty plea agreement in U.S. criminal probe
    OxyContin maker Purdue nears guilty plea agreement in U.S. criminal probe

    https://www.reuters.com/article/us-purdue-pharma-investigations-opioids/exclusive-oxycontin-maker-purdue-nears-guilty-plea-agreement-in-u-s-criminal-probe-sources-idUSKBN26S1P2

    Mike Specer REUTERS
    07 Oct 2020
    Share Share
    A $50 Billion Opioid Deal Gets Backing From 7 More States (3)
    A $50 Billion Opioid Deal Gets Backing From 7 More States (3)

    https://news.bloomberglaw.com/pharma-and-life-sciences/mckesson-j-j-opioid-settlement-offer-gains-ground-with-states

    BLOOMBERGLAW
    26 Feb 2020
    Share Share
    Drugmaker Insys wins bankruptcy court approval to sell off opioid
    Drugmaker Insys wins bankruptcy court approval to sell off opioid

    https://www.cnbc.com/2019/09/19/reuters-america-drugmaker-insys-wins-bankruptcy-court-approval-to-sell-off-opioid.html

    Nate Raymond CNBC
    19 Sep 2019
    Share Share
    Opioid Deal-Makers Cleared to Represent Cities Across U.S.
    Opioid Deal-Makers Cleared to Represent Cities Across U.S.

    https://www.bloomberg.com/news/articles/2019-09-12/negotiation-class-is-approved-for-governments-suing-over-opioids

    Jef Feeley BLOOMBERG
    12 Sep 2019
    Share Share
    Big drug distributor pays $22 million to settle US opioid charges
    Big drug distributor pays $22 million to settle US opioid charges

    https://www.cnbc.com/2019/05/24/big-drug-distributor-pays-22-million-to-settle-us-opioid-charges.html

    CNBC
    25 May 2019
    Share Share
    BlueCross BlueShield TN drops Oxycontin in favor of Collegium's competitor
    BlueCross BlueShield TN drops Oxycontin in favor of Collegium's competitor

    https://www.biopharmadive.com/news/bluecross-blueshield-tennessee-drops-oxycontin-in-favor-of-collegiums-comp/531848/

    Andrew Dunn BIOPHARMA DIVE
    08 Sep 2018
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search